Thought Leadership
Email Page
Failure to Launch: The Patent Thicket Delay of US Biosimilars
October 9, 2019
Ted Mathias, Stacie Ropka, and Chantelle Ankerman
Law360

Axinn partners Ted Mathias, Stacie Ropka, and associate Chantelle Ankerman authored the Law360 article, "Failure to Launch: The Patent Thicket Delay of US Biosimilars."

Click here to access the article. A subscription is required.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.